A Multicentric Open Label, Balanced, Randomized, Two Treatment, Two-Period, Two-Sequence, Crossover, Steady State Bioequivalence Evaluation of Clozapine Extended Release Capsule 200 mg once daily (Test Drug, Intas Pharmaceuticals Limited, India) with ClozarilÂ® 100 mg Tablets twice daily (Reference Drug, Novartis Pharmaceuticals Corporation, Usa) after multiple dose administration in Adult Schizophrenic Patients under Fasting conditions- Pilot Study - NA

Intas Pharmaceuticals Limited0 个研究点目标入组 20 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Written informed consent for participation in the study by the patient and Patientâ??s Legally Acceptable Representative (LAR)
•2.Patient has a documented clinical diagnosis of schizophrenia according to DSM IV-TR at least six months prior to screening
•3.Patients have a diagnosis of treatment-resistant schizophrenia (Treatment resistance is the failure to respond to two or more antipsychotic medications given in therapeutic dose for more than six weeks or more)
•4.Patients between 18 and 60 years of age (both inclusive)
•5.Having a BMI between 18 and 30 (both inclusive),calculated as weight in kg/height in m2
•6.Patients have been on a daily stable dose of 200 mg clozapine formulation for at least 3 month prior to screening visit
•7.Not having any significant diseases or clinically significant abnormal findings except schizophrenia.

•1.Patient with known hypersensitivity/ intolerance to clozapine or any other component of the drug.
•2.Significant orthostatic hypotension (i.e., a drop in systolic blood pressure of 30 mm Hg or more and/or a drop in diastolic blood pressure of 20 mm Hg or more on standing)
•3.Concurrent use of antihypertensive medication or any medication that might pre-dispose to orthostatic hypotension.
•4.Supine blood pressure less than 110/70 mm Hg or pulse rate less than 60 or more than 100 beat per minute at screening and Day 1.
•5.A total white blood cell count below 4000/mL, or an absolute neutrophil count <2000/ mL performed at the screening and a day prior to randomization.
•6.Pregnant or lactating females.

发起方